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Abstract
Background: We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer
patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype.
Methods: A retrospective analysis was performed for 110 metastatic breast cancer patients selected on the basis of
palliative AC treatment and the availability of immunohistochemical data for estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor-2 (HER-2/neu) status.
Results: Of the 110 patients analyzed, 71 (64.5%) were hormone receptor positive (HR+), 14 (12.7%) were HER2+,
and 25 (22.7%) were triple negative (TN). There were no differences in age, stage at diagnosis, total number of
cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver
among breast cancer subtypes. The overall response rates to AC were 55.9% for the HR+ subgroup, 42.9% for the
HER2+ subgroup, and 56.5% for the TN subgroup. The progression-free survival (PFS) in patients with HER2+ and
TN were significantly shorter than in the HR+ (median PFS, 9.1 vs 8.1 vs 11.5 months, respectively; p = 0.0002). The
overall survival (OS) was 25.4 months in the TN subgroup and 27.3 months in HER2+ subgroup. The median OS for
these two groups was significantly shorter than for patients in the HR+ subgroup (median, 38.5 months; 95% CI,
30.1-46.9 months; p < 0.0001).
Conclusions: The response to palliative AC chemotherapy did not differ among breast cancer subtypes. Despite
chemosensitivity for palliative AC, the TN subtype has a shorter overall survival than non-TN subtypes. Innovative
treatment strategies should be developed to slow the course of disease.
Background
Breast cancer encompasses a heterogeneous group of
diseases at the molecular level [1-4], and can be classi-
fied into at least five distinct subtypes by gene expres-
sion profiling: luminal A, luminal B, normal breast-like,
ERBB2, and basal like [5-10]. Basal cell-like tumors typi-
cally show low or no expression of HER2 and estrogen
receptor (ER), and high expression of genes characteris-
tic of basal epithelial cells [1,4,11-13]. These tumors
may share clinical and biologic properties with triple
negative breast cancers (TNBCs) that lack expression of
ER, progesterone receptor (PgR) and HER2 [5-8]. There
is increasing evidence that breast cancer molecular sub-
types differ in their responses to therapeutic agents.
TNBC is considered a high-risk subtype because of its
typically younger patient age, poorly differentiated
tumor characteristics, and shortened survival of patients
who often do not benefit from targeted therapies
[11-19]. Because there is insufficient data on which to
base treatment selection, no specific systemic treatment
strategy is currently recommended for the treatment of
TNBC.
* Correspondence: ajis@skku.edu
1Division of Hematology-Oncology, Department of Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-
dong Gangnam-gu, Seoul 135-710 Korea
Full list of author information is available at the end of the article
Yi et al. BMC Cancer 2010, 10:527
http://www.biomedcentral.com/1471-2407/10/527
© 2010 Yi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Anthracyclines are some of the most widely used and
effective drugs to treat patients with breast cancer in the
adjuvant setting, as well as for patients with metastatic
disease [20-25]. However, cumulative cardiotoxicity is a
major limitation to the therapeutic use of anthracyclines
and can lead to potentially fatal congestive heart failure
[26-28]. Nevertheless anthracyclines are still the most
widely used chemotherapeutic agents for the treatment
of breast cancer. Because of their wide use and proven
efficacy, anthracyclines may be especially important for
the treatment of TNBCs that are known to lack specific
therapeutic targets. Doxorubicin shows pre-clinical and
clinical activity against BRCA1-associated cancers, a clo-
sely related group of diseases with significant morpholo-
gic, phenotypic, and genetic overlap with TNBCs
[29,30]. This further suggests the potential of anthracy-
cline chemotherapy as a therapeutic option for TNBCs.
Given the interest in using doxorubicin for treating
patients with TN tumors, we have retrospectively
reviewed the medical records of metastatic breast can-
cer patients who received combination chemotherapy
with doxorubicin and cyclophosphamide (AC) as a first
line treatment. The aim of this study was to evaluate
the efficacy of AC combination therapy in patients
with TNBC. In addition, we characterized the clinico-




We performed a retrospective analysis of medical
records of patients with metastatic or recurrent breast
cancer who received AC combination chemotherapy as
a first-line treatment at Samsung Medical Center
between January 2001 and December 2006. These stu-
dies were approved by the Samsung Medical Center
Institutional Review Board.
Immunohistochemistry and molecular classification
All pathologic specimens were reviewed by two experi-
enced pathologists who determined the status of ER,
PgR, and HER2 using immunohistochemical (IHC) tech-
niques. According to the Allred scoring system, ER and
PgR negativity was defined as a total score from 0-2 by
IHC using antibodies to the ER (Immunotech, France)
and PgR (Novocastra, UK). According to National Com-
prehensive Cancer Network (NCCN) guidelines, HER2
was assessed using IHC techniques (DAKO, Santa Bar-
bara, CA, USA) and/or fluorescence in situ hybridization
(FISH). IHC grades 0 and 1 were defined as a negative
result for HER2, and the lack of HER2 amplification was
confirmed by FISH if HER2 was rated 2+ by IHC. “Tri-
ple negativity” was defined as a lack of expression of ER,
PgR, and HER2. The HER2+ subtype was defined as
HER2-positive with ER- and PR-negative, while hor-
mone receptor-positive was defined as ER- and/or PR-
positive, regardless of HER2-positivity subtypes. Ki-67
growth fractions and p53 status were assessed using
antibodies: Ki-67 (DACO, Glostrup, Denmark), and p53
(1:80, Zymed, San Francisco, CA, USA). The percentage
of positive nuclei stained for Ki-67 was calculated for
each section based on approximately 1,000 carcinoma
cell nuclei. High proliferative index was defined as 50%
or more stained nuclei. Immunoreactivity of p53 was
defined as greater than 5% of cells having distinct
nuclear staining.
Statistical analysis
The treatment response to AC was evaluated by review-
ing imaging studies according to the Response Evaluation
Criteria in Solid Tumors (RECIST). AC chemotherapy
was doxorubicin 60 mg/m2 plus cyclophosphamide 600
mg/m2 every 3 weeks. Progression-free survival (PFS)
was defined as the time from the initial date of AC che-
motherapy to the date that progressive disease was first
documented. Overall survival (OS) was defined as the
time from the initial date of AC chemotherapy to the
date of death from any cause, or the date of last follow-
up. The calculation was performed using the Kaplan-
Meier method. The log-rank method (also known as the
Mantel-Cox test) was used to compare survival rates.
The differences in responses between subtypes were esti-




Between January 2001 and December 2006, 124 patients
with metastatic breast cancer were treated with palliative
AC as a first-line treatment at Samsung Medical Center.
Immunohistochemical data for ER, PgR, and HER2 sta-
tus were available for 110 of these patients. Among
them, sixty-eight patients relapsed after surgery for inva-
sive breast cancers, and forty-two patients had meta-
static diseases at diagnoses.
Subgroups were classified on the basis of ER, PR, and
HER2 IHC findings with 71 of the 110 patients (64.5%)
being HR+, 14 patients (12.7%) HER2+, and 25 patients
(22.7%) TN. The median age at diagnosis was 45 years
(range, 24-69 years). Median disease free intervals (DFI)
after surgery among relapsed patients were 47.6 months
for HR+, 40.6 months for HER2+, and 38.7 months for
TNBC (p = 0.231). Forty patients (36.4%) were initially
diagnosed with metastatic disease. TNBCs showed
poorer histologic differentiation (Bloom-Richardson
pathologic grade III: 87.5% for TNBC, 25.0% for HER2+,
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and 37.8% for HR+, respectively; p = 0.001) and a higher
proliferative index (Ki-67 >50%: 85.7% for TNBC, 0% for
HER2+, and 31.3% for HR+, respectively; p = 0.013)
than HER2+ or HR+ subtypes. Other clinical features,
such as age, stage at diagnosis, and previous treatment
did not differ significantly among the three subtypes.
Adjuvant doxorubicin was administered to 7 patients (6
in HR+, 1 in HER2+). Hepatic metastases were more
common in the HER2+ subgroup (52.4% for HR+,
84.6% for HER2+, 45.5% for TNBC; p = 0.046). Adju-
vant endocrine treatment was performed for 43 HR+
patients (Table 1). Next to AC chemotherapy, median
numbers of palliative chemotherapy regimens were 3 for
HR+, 2 for HER2+, and 1 for TNBC (p = 0.006). Endo-
crine treatment was treated for 17 HR+ patients (24%)
as palliative aim (Table 1).
Treatment responses
Of the 110 patients, 105 (95%) with measurable lesions
had a clinical response. Two of these 105 patients had a
complete response (CR), and 56 patients achieved a par-
tial response (PR; Table 2). Both patients with CR were
HR+. The overall response rate (ORR) of 105 patients
with measurable disease was 54.3%. The ORR of HER2+
patients was slightly lower than those of patients with
HR+ or TN-subtypes, but this difference was not statis-
tically significant (42.9%, 55.9%, and 56.5%, respectively;
p = 0.542; Table 2).
Survival analysis
Progression-free survival (PFS)
The median PFS to AC chemotherapy was 9.5 months
(95% CI, 7.1-11.9 months). The median PFS of each
Table 1 Clinicopathologic characteristics of patients according to subtypes
HR+ (N = 71) HER2+ (N = 14) TN (N = 25) P value
Clinical characteristics at initial diagnosis
Median age 43.8 (30-69) 49.5 (33-65) 47.0 (24-77) .398A
Initial stage
I 9 (12.7%) 1 (7.1%) 2 (8.0%)
II 23 (32.4%) 4 (28.6%) 11 (44.0%)
III 11 (15.5%) 2 (14.3%) 2 (8.0%)
IV 25 (35.2%) 6 (42.9%) 9 (36.0%) .951B
unknown 3 (4.2%) 1 (7.1%) 1 (4.0%)
Familial History 16 (23.5%) 4 (28.6%) 7 (29.2%) .829B
DFI after surgery (median) 47.6 months 40.6 months 38.7 months 0.231 by log-rank test
Tumor characteristics
B-R.Gr. III (n = 69) 17 (37.8%) 2 (25.0%) 14 (87.5%) *.001B
P53 <5% (n = 93) 32 (55.2%) 7 (50.0%) 9 (42.9%) .621B
Ki 67 >50% (n = 25) 5 (31.3%) 0 (0%) 6 (85.7%) *.013B
Previous (neoadjuvant or adjuvant) treatments
Curative surgery. 45 (63.4%) 8 (57.1%) 15 (60.0%) .888B
Neoadju-CTx 3 (4.2%) 0 (0%) 1 (4.0%) .573B
Adjuvant CTx 35 (49.3%) 7 (50.0%) 12 (48.0%) .991B
Adjuvant doxorubicin 6 (17.1%) 1 (14.3%) 0 (0%) .048B
Adjuvant HormoTx 43 (60.6%) 0 0 < 0.0001 B
Distant Metastases
Lung 49 (74.2%) 11 (84.6%) 15 (62.5%) 0.316
Pleura 41 (57.8%) 8 (57.4%) 10 (45.5%) 0.216
Liver 33 (52.4%) 11 (84.6%) 10 (45.5%) 0.046
Brain 11 (17.7%) 3 (23.1%) 6 (27.3%) 0.629
Bone 36 (50.7%) 8 (57.1%) 10 (40.0%) 0.283
Skin 14 (19.7%) 1 (7.1%) 9 (36%) 0.081
Soft tissue 22 (31.0%) 1 (7.1%) 6 (24.0%) 0.120
Next treatment after AC chemotherapy
Median number of CTx (range) 3 (0-11) 2 (0-8) 1 (0-7) 0.006
Number of patients with HormoTx (%) 17 (24%) 0 0 0.001
Number of patients with trastuzumab Tx (%) 5 (7.0%) 4 (28.6%) 0 0.009
DFI, disease free interval; CTx, chemotherapy; HormoTx, hormonal therapy; Tx, treatment.
AContinuous variables; One way ANOVA.
BCategorical variables; Pearson’s chi-square test.
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phenotype was 8.1 months for TN (95% CI, 7.2-9.1
months), 9.1 months for HER2+ (95% CI, 1.3-16.8
months), and 11.5 months for HR+ (95% CI, 7.2-15.9
months; p = 0.0002 by log-rank test; Figure 1A).
Overall survival
With a median 55.8 months of follow-up (range, 29.2-
101.5 months), the median OS of all 110 patients was
32.4 months (95% CI, 28.5-36.3 months). The median
OS was 25.4 months (95% CI, 17.9-32.9 months) in the
TN subgroup and 27.3 months (95% CI, 9.3-45.3
months) in the HER2+ subgroup. The median OS for
these two groups was significantly shorter than OS for
HR+ patients (median, 38.5 months; 95% CI, 30.3-46.7
months; p < 0.0001). Most of the HER2+ patients did
not receive trastuzumab as first-line treatment with che-
motherapy (Figure 1B).
Time-to-Death (TTD) from the end of AC chemotherapy
There is a significant difference between patients with
TN and non-TN phenotypes in terms of TTD after AC
chemotherapy (median TTD 15.9 months, 95% CI, 7.8-
23.9 months for TN; median TTD 13.2 months, 95% CI,
9.7-16.7 months for HER2+; median TTD 24.8 months;
95% CI, 21.7-36.70 months for HR+; p < 0.0001). After
AC chemotherapy, most of the patients were treated
with additional 2nd or more lines of chemotherapies
with various regimens including platinum and taxane
agents. A median of three additional lines of palliative
chemotherapies were undertaken for HR+ patients,
whereas a median of two lines and one line of che-
motherapies were performed for HER2+ and TNBC
patients, respectively (p = 0.006). 17 of 71 (24%) of HR+
patients were treated with palliative endocrine treat-
ment. 9 of 14 HER2+ patients received palliative trastu-
zumab treatment with or without other cytotoxic agents.
Multivariate analysis for survival
The TN phenotype and HER2 positivity were identified
as independent prognostic factors for survival in Cox-
regression multivariate analysis (hazard ratio [HR] 2.03,
p = 0.011 for TN; HR 1.86, p = 0.027 for HER2 positiv-
ity) (Table 3).
Discussion
The present study demonstrates that TNBC has a simi-
lar response rate to AC combination chemotherapy
compared to other subtypes (Table 2). This encouraging
result is in agreement with published data regarding
Table 2 Treatment Response According to Subtypes (n = 105 patients with measurable diseases)
Total (n = 105) HR (n = 68) HER2 (n = 14) TN (n = 23) p
Median cycles 6.0 (1-12) 5.9 (1-12) 4.8 (1-9) 5.6 (1-9) 0.454
Response
CR 2 2 0 0
PR 55 36 6 13
SD 25 19 3 4
PD 20 11 4 5
Not evaluable 2 0 1 1
Overall response rate 57 (54.3%) 38 (55.9%) 6 (42.9%) 13 (56.5%) 0.542
CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease.
Figure 1 Kaplan-Meier survival curves according to subtypes. A Progression-Free Survival (PFS) to AC chemotherapy. B Overall Survival (OS)
to AC chemotherapy according to subgroups. C Overall Survival (OS) to AC chemotherapy in patients with TNBCs and non-TNBCs.
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chemotherapy for TNBCs, irrespective of the che-
motherapy regimen [31-33]. Despite the initial sensitivity
to chemotherapy, several studies have shown that
TNBCs carry a poor prognosis [11-13]. Our results also
showed that TNBCs had poorer PFS and OS than non-
TNBCs (Figure 1C). This finding suggests that despite
the beneficial response to treatment, chemotherapy did
not improve subsequent long-term survival of TNBC
patients. Several studies support this paradoxical feature
of high response, but poor long-term outcome
[3,4,32-34].
Chemotherapy responsiveness is usually positively cor-
related with good clinical outcomes resulting in long-
term survival [35]. However, this chemosensitivity is
insufficient to overcome biologic aggressiveness, and
rapid tumor-growth characteristics of TNBCs. In fact,
the TTD after AC chemotherapy in patients with
TNBCs was much shorter than that for HR+ patients
(median TTD, 15.9 months for TN, 13.2 months for
HER2+, and 24.8 months for HR+; p = 0.0037). This
finding suggests that another therapeutic strategy is
needed to overcome the aggressive clinical behavior,
prolong the survival time and improve the quality of life
of TNBC patients. In contrast, a longer TTD after AC
chemotherapy in patients with non-TNBCs, mainly of
the HR+ subtype, may be due to the relatively slower
tumor growth characteristics and additional benefit
from hormonal therapies with subsequent easier disease
control than for TNBCs. Thus, future treatment strate-
gies should be developed based on the heterogeneity of
the tumor. The consideration of such tumor heterogene-
ity will make a valuable contribution to the design of
individualized therapy.
Dose intensification of conventional chemotherapeutic
agents including doxorubicin may be beneficial to
extend the therapeutic index [36]. However, most of the
patients did not have durable responses. This suggests
that doxorubicin resistance can easily occur in meta-
static TNBC, perhaps due to prior exposure to doxoru-
bicin or other chemotherapeutic agents in the adjuvant
setting. Additionally, considering the poor correlation
between chemosensitivity and long-term survival in
patients with TNBCs, it is necessary to substantially pro-
long the response duration. This is because once lack of
response occurs, TNBCs appears to follow a more
aggressive and fatal clinical course TNBCs have more
aggressive tumor biology as evidenced by a higher histo-
logical grade and higher expression of Ki-67 than non-
TNBCs. Recently, a few reports have suggested the
potential use of these proliferation indexes as makers
for complex tumor characteristics [33,37,38]. Impor-
tantly, TNBCs are composed of heterogeneous disease
entities, consisting of two or more subtypes [39,40].
The interpretation of our study may be limited,
because it is a retrospective study. In addition, prior
adjuvant therapy may affect on clinical outcomes in a
metastatic setting. Despite these drawbacks, our study
may have clinical impact in treating TNBC, for which
therapeutic options are limited. The conventional treat-
ments studies here need to be supplemented with new
innovative therapeutic strategies based on an under-
standing of the biologic differences and aggressiveness
of TNBCs. As HER2 direct therapy in HER2 positive
subtype, new innovative targets for TNBC need to be
developed. Ongoing clinical trials may open the door to
better treatment outcomes. These trials evaluating new
drugs such as PARP1 inhibitors [40-42], EGFR tyrosine
kinase inhibitors [43], and antiangiogenic agents for
TNBCs in adjuvant and palliative settings.
Conclusions
TNBC had a comparable response rate to first-line AC
chemotherapy compared to non-TNBC. Nonetheless,
TNBC patients had shorter survival than non-TNBC
patients. Innovative therapeutic strategies are needed to
overcome the biologic aggressiveness of TNBCs.
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